6 resultados
The invention relates to pharmaceutical composition comprising proline derivatives, preferably Cis-4-hydroxy-I-proline (CHP) and trans-4-Hydroxy-L-proline (THP), or proline, or their salts, esters, isomers, racemates, enantiomers or pro-drugs thereof, and to the use of said compositions for the
FIELD OF THE INVENTION
The present invention relates to novel praline derivatives possessing prolyl endopeptidase-inhibitory activities, method of production thereof and pharmaceutical use thereof.
BACKGROUND OF THE INVENTION
Along with the arrival of an aging society, the medical treatment of
SUMMARY OF THE INVENTION
The compounds of the present invention are antagonists of the VLA-4 integrin ("very late antigen-4"; CD49d/CD29; or .alpha..sub.4.beta..sub.1), the .alpha..sub.4.beta..sub.7 integrin (LPAM-1 and .alpha..sub.4.beta..sub.p), and/or the .alpha..sub.9.beta..sub.1 integrin, and
BACKGROUND
Orexins are a family of homologous peptides including species orexin A, or OR-A, and orexin B, or OR-B. Orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell (1998), 92, 573-585). Orexins are produced in neurons of the lateral hypothalamus
BACKGROUND
Orexins are a family of homologous peptides including species orexin A, or OR-A, and orexin B, or OR-B. Orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell (1998), 92, 573-585). Orexins are produced in neurons of the lateral hypothalamus
BACKGROUND
Orexins are a family of homologous peptides including species orexin A, or OR-A, and orexin B, or OR-B. Orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell (1998), 92, 573-585). Orexins are produced in neurons of the lateral hypothalamus